arrow
P

Pasquale Rescigno

Candiolo Cancer Institute
H指数:40
被引数:8,123

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression

共生 Nakaseomyces glabratus 迁移至前列腺肿瘤以加速癌症进展

2026-09-090
OAAI
Corrigendum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [European Urology 83 (2023) 224–238

勘误:“B7-H3 作为晚期前列腺癌的治疗靶点” [欧洲泌尿外科杂志 83 (2023) 224–238]

2026-08-070
OAAI
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

恩扎卢替尼在转移性激素敏感前列腺癌中的应用:国际、多中心真实世界ARON-3研究的结果

2026-01-080
OAAI
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis

基于疾病体积的转移性激素敏感型前列腺癌最佳治疗方法: 系统评价和网络荟萃分析

2025-11-170
OA
177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study

177Lu-PSMA 与 cabazitaxel 在去势抵抗性前列腺癌患者中的真实世界疗效与安全性数据:ARON-3 研究结果

2025-09-120
PREAI
IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations

IUC24394-87 接受一线免疫联合治疗的转移性肾细胞癌患者Meet-URO评分更新

2025-08-290
OAAI
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis

评估内脏疾病患者中转移性激素敏感性前列腺癌的治疗效果:一项系统评价和网络Meta分析

2025-07-100
OAAI
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience

真实世界结局与分子分型:肺转移性去势抵抗性前列腺癌患者的长期多中心研究经验

2025-06-010
OAAI
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study

阿帕卢他胺在转移性去势敏感前列腺癌中的应用:多中心真实世界ARON-3研究的结果

2024-11-010
OAAI
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
2024-10-011
OA
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

放疗加pembrolizumab治疗晚期尿路上皮癌: 来自ARON-2真实世界研究的结果

2024-08-270
OAAI
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy

将STING激动剂靶向前列腺肿瘤的血管周围巨噬细胞可延迟对雄激素剥夺疗法的抵抗力

2024-07-252
OAAI
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

mRCC骨转移患者的钠水平和免疫治疗功效: Meet-Uro 15研究的子分析

2024-07-055
OAAI